表紙
市場調查報告書
商品編碼
891071

磷酸肌醇3-激酶(PI3k)抑制劑的全球市場:2019年∼2023年

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market 2019-2023

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 127 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

磷脂醯肌醇3-激酶(PI3K)抑製劑限制PI3K酶並有助於控制癌症。2018年,獲得慢性淋巴性白血病(CLL)市場區隔最大的市場佔有率,這個趨勢在預測期間內也將持續。諸如CLL和FL高患病率以及增加新癌症病例等因素將在CLL市場區隔中發揮重要作用,以維持其市場地位。此外,全球磷酸肌醇3-激酶抑製劑市場由於最近的認證,策略性聯盟,尤其是藥物指定等要素,在預測期間內將以約5%的年複合成長率成長。但,由於藥物的採用低,臨床試驗的失敗,及嚴格法規,可能會妨礙磷酸肌醇3-激酶抑製劑產業在預測期內的成長。

本報告提供全球磷酸肌醇3-激酶(PI3k)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • CLL
  • FL
  • 其他
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區風景

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 研究適應的擴大
  • 償付計劃
  • 癌症的認識的高漲

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31677

About this market

Phosphoinositide 3-kinase (PI3K) inhibitors restricts PI3K enzymes and help in controlling cancer. Technavio's phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and other indications. Our analysis also considers the sales of phosphoinositide 3-kinase inhibitors in Asia, Europe, North America, and ROW. In 2018, the CLL segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high prevalence of CLL and FL and increasing new cases of cancer will play a significant role in the CLL segment to maintain its market position. Also, our global phosphoinositide 3-kinase inhibitors market report also looks at factors such as recent approvals, strategic alliances, and special drug designations. However, low adoption of drugs, clinical trial failures, and stringent regulations may hamper the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Overview

Recent approvals

Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need. Chemotherapies are widely used for the treatment of several types of cancer, including lymphomas. However, chemotherapies have some limitations, which reduces patient adherence toward the treatment. Such factors have fueled exhaustive research on target therapies such as PI3K inhibitors for the treatment of cancer. Several drugs have been approved, such as copanlisib (ALIQOPA) for the treatment of FL, in September 2017. Thus, recent approvals are expected to fuel the PI3K inhibitors market to grow at a CAGR of about 5% during the forecast period.

Reimbursement programs

The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the PI3K inhibitors market for a long time. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the PI3K inhibitors market size during the forecast period.

For the detailed list of factors that will drive the global phosphoinositide 3-kinase inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphoinositide 3-kinase inhibitors manufacturers, that include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.

Also, the phosphoinositide 3-kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • CLL - Market size and forecast 2018-2023
  • FL - Market size and forecast 2018-2023
  • Other indications - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Expansion of research indications
  • Reimbursement programs
  • Growing awareness about cancer

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Application - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by application
  • Exhibit 19: CLL - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: CLL - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: FL - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: FL - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Other indications - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: New cases of cancer in US 2015
  • Exhibit 25: Other indications - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by application
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Proportion of geriatric population in Asia 2007 and 2017
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Drug designations
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Approved drugs with respect to their cancer indications
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: Bayer AG - Vendor overview
  • Exhibit 54: Bayer AG - Product segments
  • Exhibit 55: Bayer AG - Organizational developments
  • Exhibit 56: Bayer AG - Geographic focus
  • Exhibit 57: Bayer AG - Segment focus
  • Exhibit 58: Bayer AG - Key offerings
  • Exhibit 59: Bayer AG - Key customers
  • Exhibit 60: Gilead Sciences Inc. - Vendor overview
  • Exhibit 61: Gilead Sciences Inc. - Business segments
  • Exhibit 62: Gilead Sciences Inc. - Organizational developments
  • Exhibit 63: Gilead Sciences Inc. - Geographic focus
  • Exhibit 64: Gilead Sciences Inc. - Key offerings
  • Exhibit 65: Gilead Sciences Inc. - Key customers
  • Exhibit 66: Novartis AG - Vendor overview
  • Exhibit 67: Novartis AG - Business segments
  • Exhibit 68: Novartis AG - Organizational developments
  • Exhibit 69: Novartis AG - Geographic focus
  • Exhibit 70: Novartis AG - Segment focus
  • Exhibit 71: Novartis AG - Key offerings
  • Exhibit 72: Novartis AG - Key customers
  • Exhibit 73: TG Therapeutics Inc. - Vendor overview
  • Exhibit 74: TG Therapeutics Inc. - Business segments
  • Exhibit 75: TG Therapeutics Inc. - Organizational developments
  • Exhibit 76: TG Therapeutics Inc. - Key offerings
  • Exhibit 77: TG Therapeutics Inc. - Key customers
  • Exhibit 78: Verastem Inc. - Vendor overview
  • Exhibit 79: Verastem Inc. - Business segments
  • Exhibit 80: Verastem Inc. - Organizational developments
  • Exhibit 81: Verastem Inc. - Key offerings
  • Exhibit 82: Verastem Inc. - Key customers
  • Exhibit 83: Validation techniques employed for market sizing
  • Exhibit 84: Definition of market positioning of vendors